Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Other Non-Current Liabilities (2016 - 2025)

Avanos Medical (AVNS) has disclosed Other Non-Current Liabilities for 13 consecutive years, with $13.5 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities rose 206.82% to $13.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.5 million through Dec 2025, up 206.82% year-over-year, with the annual reading at $13.5 million for FY2025, 206.82% up from the prior year.
  • Other Non-Current Liabilities hit $13.5 million in Q4 2025 for Avanos Medical, down from $20.7 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $28.0 million in Q1 2022 to a low of $4.3 million in Q2 2025.
  • Historically, Other Non-Current Liabilities has averaged $14.0 million across 5 years, with a median of $10.8 million in 2021.
  • Biggest YoY gain for Other Non-Current Liabilities was 206.82% in 2025; the steepest drop was 59.05% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $9.1 million in 2021, then soared by 125.27% to $20.5 million in 2022, then tumbled by 51.22% to $10.0 million in 2023, then plummeted by 56.0% to $4.4 million in 2024, then soared by 206.82% to $13.5 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for AVNS at $13.5 million in Q4 2025, $20.7 million in Q3 2025, and $4.3 million in Q2 2025.